| Abstract | Acute massive hemoptysis is a rare complication of pulmonary injury and contusion, and it is particularly difficult to manage in the nontertiary care setting. Recombinant activated coagulation factor VII (rFVIIa) is a prothrombotic drug that is increasingly being used to treat coagulopathy in massively exsanguinating trauma patients. We report a case in which recombinant activated coagulation factor VII successfully controlled massive hemoptysis and improved ventilation from a severe pulmonary contusion in a noncoagulopathic patient who suffered a penetrating thoracic injury in a military setting in Afghanistan. |
| Authors | Homer C N Tien, Michael R C Gough, Robert Farrell, John Macdonald
(Affiliation: The Trauma Program and the Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada. homer.tien at sunnybrook.ca)
|
| Journal | The Annals of thoracic surgery
(Ann Thorac Surg)
Vol. 84
Issue 4
Pg. 1373-4
(Oct 2007)
ISSN: 1552-6259 Netherlands |
| PMID | 17889002
(Publication Type: Case Reports, Journal Article)
|
| Chemical References |
- Hemostatics
- Recombinant Proteins
- recombinant FVIIa
- Factor VIIa
|
| Topics |
- Adult
- Combined Modality Therapy
- Dose-Response Relationship, Drug
- Factor VIIa
(administration & dosage)
- Follow-Up Studies
- Hemoptysis
(etiology, therapy)
- Hemostatics
(administration & dosage)
- Humans
- Lung
(injuries)
- Male
- Recombinant Proteins
(administration & dosage)
- Risk Assessment
- Severity of Illness Index
- Thoracic Injuries
(complications, diagnosis)
- Thoracotomy
(methods)
- Treatment Outcome
- Wounds, Gunshot
(complications, diagnosis)
|
